Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia

Robin R. Vann, Carol Karp

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Objective: To evaluate the role of combined subconjunctival and topical interferon alfa-2b (IFNα2b) in the treatment of conjunctival and corneal intraepithelial neoplasia (CIN). Design: Noncomparative case series. Participants: Six patients with histologically proven CIN or recurrences of histologically proven CIN were studied prospectively. Intervention: Patients were given a single subconjunctival/perilesional injection of recombinant IFNα2b (Schering Plough, Kenilworth, NJ) 3 million international units (IU) in 0.5 ml and then started receiving topical interferon drops (1 million U/ml) four times a day. Patients were followed weekly until complete resolution of the tumor. After 1 week, patients with minimal response while receiving topical therapy were retreated with perilesional injections three times a week until resolution. Patients received topical interferon drops for a month after clinical resolution of the lesion. Main Outcome Measures: Patients were followed clinically and photographically for evidence of tumor resolution. Results: The authors present a series of six patients who were treated successfully with a combination of subconjunctival/perilesional and topical IFNα2b. All six patients had complete clinical resolution of the CIN lesion within 6 weeks of initiation of treatment. In the time of follow-up (average, 7.2 months; range, 2-11 months), there have been no treatment failures or recurrences. Conclusion: IFNα2b may be a viable medical alternative to surgical excision for primary or recurrent CIN.

Original languageEnglish
Pages (from-to)91-97
Number of pages7
JournalOphthalmology
Volume106
Issue number1
StatePublished - Jan 1 1999

Fingerprint

interferon alfa-2b
Neoplasms
Interferons
Recurrence
Injections
Treatment Failure

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia. / Vann, Robin R.; Karp, Carol.

In: Ophthalmology, Vol. 106, No. 1, 01.01.1999, p. 91-97.

Research output: Contribution to journalArticle

@article{83caf7e6f3ce42d3be8d46ea908460fe,
title = "Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia",
abstract = "Objective: To evaluate the role of combined subconjunctival and topical interferon alfa-2b (IFNα2b) in the treatment of conjunctival and corneal intraepithelial neoplasia (CIN). Design: Noncomparative case series. Participants: Six patients with histologically proven CIN or recurrences of histologically proven CIN were studied prospectively. Intervention: Patients were given a single subconjunctival/perilesional injection of recombinant IFNα2b (Schering Plough, Kenilworth, NJ) 3 million international units (IU) in 0.5 ml and then started receiving topical interferon drops (1 million U/ml) four times a day. Patients were followed weekly until complete resolution of the tumor. After 1 week, patients with minimal response while receiving topical therapy were retreated with perilesional injections three times a week until resolution. Patients received topical interferon drops for a month after clinical resolution of the lesion. Main Outcome Measures: Patients were followed clinically and photographically for evidence of tumor resolution. Results: The authors present a series of six patients who were treated successfully with a combination of subconjunctival/perilesional and topical IFNα2b. All six patients had complete clinical resolution of the CIN lesion within 6 weeks of initiation of treatment. In the time of follow-up (average, 7.2 months; range, 2-11 months), there have been no treatment failures or recurrences. Conclusion: IFNα2b may be a viable medical alternative to surgical excision for primary or recurrent CIN.",
author = "Vann, {Robin R.} and Carol Karp",
year = "1999",
month = "1",
day = "1",
language = "English",
volume = "106",
pages = "91--97",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Perilesional and topical interferon alfa-2b for conjunctival and corneal neoplasia

AU - Vann, Robin R.

AU - Karp, Carol

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Objective: To evaluate the role of combined subconjunctival and topical interferon alfa-2b (IFNα2b) in the treatment of conjunctival and corneal intraepithelial neoplasia (CIN). Design: Noncomparative case series. Participants: Six patients with histologically proven CIN or recurrences of histologically proven CIN were studied prospectively. Intervention: Patients were given a single subconjunctival/perilesional injection of recombinant IFNα2b (Schering Plough, Kenilworth, NJ) 3 million international units (IU) in 0.5 ml and then started receiving topical interferon drops (1 million U/ml) four times a day. Patients were followed weekly until complete resolution of the tumor. After 1 week, patients with minimal response while receiving topical therapy were retreated with perilesional injections three times a week until resolution. Patients received topical interferon drops for a month after clinical resolution of the lesion. Main Outcome Measures: Patients were followed clinically and photographically for evidence of tumor resolution. Results: The authors present a series of six patients who were treated successfully with a combination of subconjunctival/perilesional and topical IFNα2b. All six patients had complete clinical resolution of the CIN lesion within 6 weeks of initiation of treatment. In the time of follow-up (average, 7.2 months; range, 2-11 months), there have been no treatment failures or recurrences. Conclusion: IFNα2b may be a viable medical alternative to surgical excision for primary or recurrent CIN.

AB - Objective: To evaluate the role of combined subconjunctival and topical interferon alfa-2b (IFNα2b) in the treatment of conjunctival and corneal intraepithelial neoplasia (CIN). Design: Noncomparative case series. Participants: Six patients with histologically proven CIN or recurrences of histologically proven CIN were studied prospectively. Intervention: Patients were given a single subconjunctival/perilesional injection of recombinant IFNα2b (Schering Plough, Kenilworth, NJ) 3 million international units (IU) in 0.5 ml and then started receiving topical interferon drops (1 million U/ml) four times a day. Patients were followed weekly until complete resolution of the tumor. After 1 week, patients with minimal response while receiving topical therapy were retreated with perilesional injections three times a week until resolution. Patients received topical interferon drops for a month after clinical resolution of the lesion. Main Outcome Measures: Patients were followed clinically and photographically for evidence of tumor resolution. Results: The authors present a series of six patients who were treated successfully with a combination of subconjunctival/perilesional and topical IFNα2b. All six patients had complete clinical resolution of the CIN lesion within 6 weeks of initiation of treatment. In the time of follow-up (average, 7.2 months; range, 2-11 months), there have been no treatment failures or recurrences. Conclusion: IFNα2b may be a viable medical alternative to surgical excision for primary or recurrent CIN.

UR - http://www.scopus.com/inward/record.url?scp=0032621393&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032621393&partnerID=8YFLogxK

M3 - Article

VL - 106

SP - 91

EP - 97

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 1

ER -